anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Cichorium glandulosum, a common traditional Chinese medicine used by Uyghur and Mongolian ethnic groups, is recognized for its potential to ameliorate metabolic disorders. However, the specific efficacy and mechanisms of Cichorium glandulosum in treating the comorbidity of hyperuricaemia and hyperlipidaemia remain unexplored. This study aims to explore the pharmacological effects and mechanisms of Cichorium glandulosum on this comorbidity through a combination of animal experiments, network pharmacology, and molecular docking techniques. A rat model of hyperuricaemia combined with hyperlipidaemia was established through a high-fat and high-purine diet, and the effective parts of the aqueous extract of Cichorium glandulosum to reduce uric acid and lipid levels were screened and the components of the parts were analysed by LC-MS/MS. The active components, core targets, and key pathways were analysed using network pharmacology and validated by molecular docking. Animal experimental results indicated that the n-butanol extract of Cichorium glandulosum showed a significant therapeutic effect on this comorbidity. Analysis of the n-butanol extract yielded 35 active ingredients and 138 intersecting targets related to diseases. Key targets identified through compound-target-pathway (C-T-P) and Protein-Protein Interaction (PPI) analyses included RELA, CASP3, PTGS2, TNF, and ESR1. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses revealed 2515 functional items and 164 pathways, respectively. Molecular docking demonstrated that isochlorogenic acid A, baicalin, chicoric acid, and lactucopicrin showed the highest binding affinity to RELA and PTGS2. The n-butanol fraction from the aqueous extract of Cichorium glandulosum was found to reduce uric acid and lipid levels effectively. In summary, Cichorium glandulosum has a therapeutic effect on hyperuricaemia combined with hyperlipidaemia through its multi-component, multi-target, and multi-pathway characteristics.
The invention relates to a freckle removing medicine composition and a preparing method thereof. The freckle removing medicine composition is prepared from, by weight, 50-60 parts of rhizoma nardostachyos, 50-60 parts of zingiber kawagoii hayata, 40-50 parts of elsholtzia, 40-50 parts of radix angelicae, 40-50 parts of rhizoma bletillae, 40-50 parts of divaricate saposhnikovia roots, 50-70 parts of ligusticum sinense oliver, 50-60 parts of luffa, 30-40 parts of white muscardin silkworms, 50-60 parts of lemons and 50-60 parts of pomegranates. A scientific technological method is adopted, effective ingredients of the raw materials can be effectively extracted, the medicine effect of the medicine composition can permeate into the human skin, and good freckle removing and whitening effects can be achieved. Lemons and pomegranates can effectively resist oxidation and effectively prevent melanin from being formed. By means of clinical trials of the medicine composition on patients with various face stains, black skin and other pigmentation, the effective rate reaches 90%. The medicine composition especially has a better curative effect on face stains, black skin and pigmentation matter of pregnant and postpartum women.
The invention is concerned with a kind of anti-hypoxic tea to enhance the anti-hypoxic enginery of people body. It relates to non-fruit lycium barbarum bud, green tea, medlar and rhodiola sachalinensis. The salidroside of the rhodiola sachalinensis grew in the high altitude and lack of air condition acts on people body and increases the anti-hypoxic ability of body, restrains and reduces the hoist of people blood pressure. The kukoamine A of non-fruit lycium barbarum bud plant excites the backbone and twig assistant sympathetic nerves of people. The abundant matter, such as lycium larbarum polysaccharides, vitamin A of medlar to increase the amount of leucocyte reducing arose by cyclophosphamide and CO60. They all increases enginery and adjusts immunity of people, and during the adjustment process of immunity system to set anti-hypoxic enginery of people body. It affords the tea to increase the anti-hypoxic enginery of people body and lead the direction to realize the anti-hypoxic of people body through bite and sup with huge country and international market.
Group A was given hot pack at knee joint for 10-15min. Then the Mulligan's Squeeze Technique was applied. The patient in supine lying. The therapist placed thumb on joint line tenderness of knee. With the other thumb, the therapist reinforced the first thumb. The patient was asked to slowly flex knee. The therapist maintaining the thumb contact, applied the force centrally. The force was increased progressively as the knee moved towards full range of available flexion. At the end range, the therapist assisted the tibia to move towards more flexion with ulnar border of their hand. This position was maintained for a few seconds and the overpressure was applied. Then patient was asked to perform knee extension. As the knee moved towards extension the force applied from both thumbs was progressively reduced. At maximal extension, no force was applied. This was repeated 10 times in each set with total 3 sets. After this stretching and strengthening exercises were performed by patient.
An aspect of the present disclosure provides a synergistic composition that exhibits an anti-proliferative activity, the composition including: therapeutically effective amount of Turmeric (Curcuma spp.); and therapeutically effective amount of Cow urine (Gomutra). In an embodiment, the composition includes Turmeric in an amount ranging from about 0.25% to about 99.75% by weight of the composition. In an embodiment, the composition includes Cow urine in an amount ranging from about 0.25% to about 99.75% by weight of the composition. In an embodiment, the composition includes Turmeric in an amount of 33% by weight of the composition and Cow urine in an amount of 67% by weight of the composition. The composition comprising a combination of Cow urine and Turmeric extract exhibits unexpected synergistic effect and significantly controls the growth of cancerous Human Breast Cancer Cell Line as compared to Cow urine and extract of Turmeric when used alone.
The IBH-P intervention addresses four areas: 1) assessment of emotional and behavioral adjustment, 2) parental education on important supports for emotional and behavioral health, 3) modeling and guidance on nurturing and responsive parenting, and 4) addressing parental concerns about and promoting child self-regulation. The primary focus of IBH-P is promoting infant self-regulation by teaching mothers how to soothe and calm their baby. Trauma-informed and relationship building methods are emphasized to acknowledge maternal experiences with violence and adversity and the desire to establish a strong working alliance. IBH-P is distinguished from Bright Futures through its emphasis on experiential learning, modeling of effective parenting skills, in-session practice and feedback, and proactive problem-solving. Families in IBH-P will receive all standard care elements of the well-child visit including pediatrician implementation of Bright Futures curriculum.
The invention discloses a medicament for treating chronic enteritis, belonging to the Chinese traditional medicine field. The medicament is prepared by Bamboo Shavings 10-15g, Chinese Pulsaiilla Root 10-20g, Golden Thread 5-10g, Bittet Orange 10-20g, Whiteflower Patrinia Herb 10-20g, Chinese Angelica 6-15g, Coix Seed 20-30g, Largehead Atractylodes Rhizome 10-20g, Lobed Kudzuvine Root 16-25g, Amomum Fruit 5-15g, haricot bean 10-20g, roasted Licorice Roots Northwest 3-8g, Nutgrass Galingale Rhizome 5-15g and Combined Spicebush Root 5-10g. The raw materials are purified and placed in an earthen pot, and then 500ml water is added into the earthen pot to be decocted with the drugs for half an hour. One dose is taken for one day and in two times. The invention has the effects of invigorating the spleen and mid-energizer warming, removing dampness through diuresis and removing stagnancy, harmonizing intestine-stomach and treating both cold and heat. The invention also has the advantages that the raw materials are low in cost and easy to collect and has no side effects.
A cross-sectional study was conducted from May 2017 to March 2019. A participatory epidemiological appraisal was used to gain a rapid overview of the range of camel calf health problems and traditional management, a measure of the importance that people place on each of them, and to identify and prioritize economically important diseases in target zones. The most important constraints to camel production were identified to be the widespread prevalence of diseases such as camelpox, contagious ecthyma, calf scour, ticks, and nonspecific pneumonia; poor management and husbandry practices such as restrictive colostrum feeding, lack of concentrate and salt supplementation and inappropriate housing; shortage of feed; and scarce seasonal variation in water. Additionally, the livestock herders not only showed their knowledge of common camel calf diseases for affected organs and symptoms but also indicated the seasonality of disease occurrences with strong agreement (W = 0.899, P< 0.003) among the informants of all focus group discussions. The overall prevalence of mange, tick infestation, and bacteria-induced diarrhea in the study area was found to be 36.3%, 36%, and 74%, respectively. Sarcoptes scabie var. cameli was the only identified mite species from mange-infested calves, while Hyalomma, Rhipicephalus, and Amblyoma were the most commonly identified tick species. Similarly, the overall prevalence of diarrhea was 74% among this about 34.6% was caused by E. coli while 38.9% was affected by Salmonella and E. coli. Therefore, based on these findings, five diseases have been prioritized as the most significant calf diseases in the area (Camelpox, contagious ecthyma, and causes of pneumonia among camel calves). Improving veterinary health infrastructure and capacity, and increasing community awareness on camel health constraints are also recommended to enhance optimal camel calf rearing.
Testosterone 1.62% gel will be applied daily by the participants (all participants will be trained in the application process and will be given printed instructions). The intervention will be for 6 months.
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The STRIVERDI RESPIMAT clinical development program included seven dose-ranging trials and eight confirmatory trials. Four of the confirmatory trials were 6-week cross-over trials and four were 48-week parallel group trials. Adverse reactions observed in the dose-ranging trials and four 6-week cross-over trials were consistent with those observed in the 48-week parallel group trials, which formed the primary safety database.

The primary safety database consisted of pooled data from the four 48-week double-blind, active and placebo-controlled, parallel group confirmatory clinical trials. These trials included 3104 adult COPD patients (77% males and 23% females) 40 years of age and older. Of these patients, 876 and 883 patients were treated with STRIVERDI RESPIMAT 5 mcg and 10 mcg once-daily, respectively. The STRIVERDI RESPIMAT groups were composed of mostly Caucasians (66%) with a mean age of 64 years and a mean percent predicted FEV1 at baseline of 44% for both the 5 mcg and 10 mcg treatment groups. Control arms for comparison included placebo in all four trials plus formoterol 12 mcg in two trials.

In these four clinical trials, seventy-two percent (72%) of patients exposed to any dose of STRIVERDI RESPIMAT reported an adverse reaction compared to 71% in the placebo group. The proportion of patients who discontinued due to an adverse reaction was 7.2% for STRIVERDI RESPIMAT treated patients compared to 8.8% for placebo treated patients. The adverse reaction most commonly leading to discontinuation was worsening COPD. The most common serious adverse reactions were COPD exacerbation, pneumonia, and atrial fibrillation.

Table 1 shows all adverse drug reactions reported by at least 2% of patients (and higher than placebo) who received STRIVERDI RESPIMAT 5 mcg during the 48-week trials.

Additional adverse reactions that occurred in greater than 2% (and higher than placebo) of patients exposed to STRIVERDI RESPIMAT 10 mcg were pneumonia, constipation, and pyrexia.

Lung cancers were reported in 6 (0.7%), 3 (0.3%), and 2 (0.2%) patients who received STRIVERDI RESPIMAT 10 mcg, 5 mcg, and placebo, respectively.
The invention discloses an integrated implant which comprises an implanting portion and a fixed portion connected with the implanting portion. Artificial teeth are arranged on the fixed portion and integrally formed. The ends of the implanting portion are manufactured into the shapes of tips which are made of alloy, so that the implanting portion can be conveniently implanted into the alveolar bone. Rotary threads are arranged in the middle of the fixed portion, so that rotation of a rotary tool is facilitated. The artificial teeth and the implant are integrally formed, so that operation steps are reduced. The ends of the implanting portion are manufactured into the shapes of tips, so that implanting portion can be conveniently guided into the alveolar bone and quickly implanted into the tissue. Patients recover easily after operation.
Adult, lab-reared, highland deer mice acclimate to hypoxia by increasing reliance on carbohydrates to fuel exercise. Yet neither the underlying mechanisms for this shift in fuel use nor the impact of lifetime hypoxia exposure experienced in high alpine conditions, are fully understood. Thus, we assessed the use of fuel during exercise in wild highland deer mice running in their native environment. We examined a key step in muscle carbohydrate oxidation - the regulation of pyruvate dehydrogenase (PDH) - during exercise at altitude in wild highlanders and in first generation (G1) lab-born and -raised highlanders acclimated to normoxia or hypoxia. PDH activity was also determined in the gastrocnemius of G1 highlanders using an in situ muscle preparation. We found that wild highlanders had a high reliance on carbohydrates while running in their native environment, consistent with data from hypoxia-acclimated G1 highlanders. PDH activity in the gastrocnemius was similar post exercise between G1 and wild highlanders. However, when the gastrocnemius was stimulated at a light work rate in situ, PDH activity was higher in hypoxia-acclimated G1 highlanders and was associated with lower intramuscular lactate levels. These findings were supported by lower PDH kinase 2 protein production in hypoxia-acclimated G1 mice. Our findings indicate that adult phenotypic plasticity in response to low oxygen is sufficient to increase carbohydrate reliance during exercise in highland deer mice. Additionally, variation in PDH regulation with hypoxia acclimation contributes to shifts in whole-animal patterns of fuel use and is likely to improve exercise performance via elevated energy yield per mole of O2. .
BACKGROUND: Higher prevalence of obesity has been observed among women compared to men, which can be explained partly by the higher consumption of sweets and physical inactivity. Obesity can alter immune cell infiltration, and therefore increase the susceptibility to develop chronic inflammation and metabolic disorders. In this study, we aimed to explore the association between free sugar intake and other unhealthy lifestyle habits in relation to the proportion of circulating iNKT cells among women with healthy weight and women experiencing overweight and obesity.
METHODS: A cross-sectional study was conducted on 51 Saudi women > 18 years, wherein their daily free sugar intake was assessed using the validated Food Frequency Questionnaire. Data on smoking status, physical activity, and supplement use were also collected. Anthropometric data including height, weight, waist circumference were objectively measured from each participants. The proportion of circulating iNKT cells was determined using flow cytometry.
RESULTS: Smoking, physical activity, supplement use, and weight status were not associated with proportion of circulating iNKT cells. Significant association was found between proportion of circulating iNKT cells and total free sugar intake and free sugar intake coming from solid food sources only among women experiencing overweight and obesity (Beta: -0.10: Standard Error: 0.04 [95% Confidence Interval: -0.18 to -0.01], p= 0.034) and (Beta: -0.15: Standard Error: 0.05 [95% Confidence Interval: -0.25 to -0.05], p= 0.005), respectively.
CONCLUSION: Excessive free sugar consumption may alter iNKT cells and consequently increase the risk for chronic inflammation and metabolic disorders.
A one-week screening period will occur, during which pain scores and sleep scores will be tabulated. Following screening, a 4-week period of single blind treatment with flexible dosing of nabilone at 0.5 - 4 mg/day will initiate.
The invention relates to medicine, in particular to endocrinology. The inventive method for potentiating the therapeutic effect of exenatide consists in injecting the efficient quantity thereof in combination with the efficient quantity of dalargin. The preferred therapeutic effects of the invention consist in reducing pathologically high levels of glucose and cholesterol in the blood of diabetics. The inventive method for treating pancreatic diabetes consists in injecting the efficient quantity of exenatide in combination with the efficient quantity of dalargin. The invention discloses the use of the exenatide and dalargin combination for producing a medicinal preparation for treating pancreatic diabetes. A medicinal preparation which is used for treating pancreatic diabetes and which contains the efficient quantity of exenatide, the efficient quantity of dalargin and a pharmaceutically acceptable carrier or solvent and a method for the preparation thereof are also disclosed. A medicinal preparation which is used for treating pancreatic diabetes and which is embodied in the form of a set containing the exenatide and dalargin medicinal preparations and a method for the use of said medicinal preparation are also disclosed.
The invention discloses a pharmaceutical composition for resisting fungal infection, and a preparation method, a preparation and application thereof. The antifungal infection pharmaceutical composition is prepared from, by weight, 20-30 parts of hydrangea aspera, 20-30 parts of murraya paniculata, 20-30 parts of radix sophorae flavescentis, 20-30 parts of cortex phellodendri and 10-20 parts of euphorbia hirta. The preparation method comprises the steps of pretreatment, extraction and post-treatment. The preparation is prepared by adding pharmaceutically acceptable auxiliary materials into the antifungal infection pharmaceutical composition and preparing into tablets, capsules, granules, pills and tinctures. The application of the invention is the application of the antifungal infection pharmaceutical composition in preparing medicines for preventing/treating fungal infection diseases. The antifungal infection resisting medicine composition prepared by the invention has the function of treating tinea manus, tinea pedis and onychomycosis.
The COVID-19 Treatment Guidelines Panel (the Panel) recommends using nirmatrelvir 300 mg with ritonavir 100 mg (Paxlovid) orally (PO) twice daily for 5 days in nonhospitalized adults with mild to moderate COVID-19 who are at high risk of disease progression (). Treatment should be initiated as soon as possible and within 5 days of symptom onset. Ritonavir-boosted nirmatrelvir is available through an FDA EUA for the treatment of mild to moderate COVID-19 in nonhospitalized adolescents aged 12 to 17 years and weighing ≥40 kg.4 For recommendations on using ritonavir-boosted nirmatrelvir in nonhospitalized children with COVID-19.
PURPOSE:An antilipemic agent, containing live or dead microbial cells of a bacterium belonging to the genus Streptococcus as an active constituent, and capable of lowering the blood serum cholesterol, blood serum triglycerides, etc. with low toxicity. CONSTITUTION:An antilipemic agent containing live or dead microbial cells of a bacterium belonging to the genus Streptococcus as an active constituent. Streptococcus avium Mi 33 strain and Streptococcus YIT 2024 strain are particularly effective bacteria. The live or dead microbial cells are preferably administered in the form of a suspension prepared by suspending the microbial cells in a suspending medium, e.g. 1-20% skimmilk powder, or a powder prepared by freeze-drying the resultant suspension. The agent is capable of lowering the blood serum triglycerides, blood serum cholesterol, arteriosclerotic index, etc. to improve the hyperlipemia. The agent may be added to various foods for use as a preventing food for the hyperlipemia.
Patients who underwent arthroscopic rotator cuff repair surgery (n=10). They were implemented physiotherapy after the surgery once a week for 12 weeks. They were encouraged to do exercises 3 to 5 times every day.
The study will investigate the research questions in three stages. In the first stage four patients will be treated individually. In the second stage two groups of four patients will be treated, with at least a 1:1 ratio between therapists and patients per group. In the third stage 30 patients will be treated in groups of about four patients per group, with at least a 1:1 ratio between therapists and patients per group. The primary outcome measure is changes in PTSD-related symptoms as measured using the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5). Acceptability will be measured as the proportion of patients accepting treatment when offered, while attrition is measured as the proportion of patients that withdraw from treatment after it has started. Several other measures will be collected to measure treatment satisfaction, related symptoms, and functional impairment.
Clofarabine 52 mg/m² to assess feasibility in ALL patients. Patients receive Cycle 1 (14-42 days) Cytarabine IT (aged based dosage 1-1.99 30 mg, 2-2.99 50 mg, ≥ 3 years 70 mg on Day 0, Clofarabine IV (dosage 52 mg/m2/dose) on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5. Cycle 2 (14-42 days) Methotrexate IT (age based dosage 1-1.99 8 mg, 2-2.99 10 mg, ≥ 3 12 mg) on day 1, Clofarabine IV 52 mg/m2/dose on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5. Maintenance cycles 1-10 (14-42 days each) Methotrexate IT (age based dosage 1-1.99 8 mg, 2-2.99 10 mg, ≥ 3 12 mg) on day 1, Clofarabine IV 52 mg/m2/dose on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5.
PURPOSE: A cosmetic composition containing hexylene glycol is provided to prevent denaturation and ensure moisturization without irritation. CONSTITUTION: A cosmetic composition contains 0.1-10 weight parts of hexylene glycol of chemical formula 1 based on 100 weight part. The addition of hexylene glycol improves antibacterial activity of the cosmetic composition. The composition further contains 0.1-10 weight parts of ethylhexyl glycerin of chemical formula 2. The athylhexyl glycerin enhances antibacterial function and moisturization. The cosmetic composition is used in the form of lotion, cream, pack, cleansing, or essence.
Participants in this group have PKU and were deemed unresponsive to the drug. They will attend their first study visit, and proceed through the meal challenge without BH4. They will then take BH4 for 2 weeks. The second meal challenge will be performed with the participant's final dose of BH4.